Particle Sciences to open new commercial facility

New facility will offer customers the full range of services from development through to commercial-scale manufacturing

Located on its existing site in Bethlehem, PA, it is as part of an overall business unit investment of $60 million.

The 5,000 sq. ft facility will leverage Particle Sciences’s knowledge in complex formulations and drug product manufacturing, enabling the CDMO to offer customers the full range of services from development through to commercial-scale manufacturing.

Located next to the existing development and clinical trial manufacturing site, it will accommodate both sterile and non-sterile finished drug products, such as ophthalmics, drug-device combination products, injectables, micro- and nanoparticulate formulations and lyophilized drugs.

The new space was purpose-built for more complex drug products and features state-of-the-art utilities to accommodate the production of Water for Injection (WFI) and clean steam for clean-in-place processes.

Dr Robert Lee, newly-appointed president at Particle Sciences, said “Our new facility will extend our manufacturing capabilities to phase III clinical trial materials and commercial product manufacturing.

“Present and future clients will benefit from the wide variety of dosage forms that the facility can handle as well as our ability to accommodate the smaller commercial batch volumes that other CMOs will not take on.”

The new facility forms part of a wider investment by Lubrizol LifeSciences to strengthen its key capabilities, focusing on new product solutions, capacity expansion and additional commercial manufacturing.

It is expected to increase employment at Particle Sciences by 30% with jobs ranging from production and quality control positions to support functions such as analytical services.